Weiss Ratings Reaffirms Hold (C) Rating for Theravance Biopharma (NASDAQ:TBPH)

Theravance Biopharma (NASDAQ:TBPH)‘s stock had its “hold (c)” rating reiterated by equities researchers at Weiss Ratings in a research note issued to investors on Saturday,Weiss Ratings reports.

Other equities analysts have also issued research reports about the stock. B. Riley initiated coverage on shares of Theravance Biopharma in a report on Friday, September 12th. They issued a “buy” rating and a $28.00 target price on the stock. Zacks Research lowered Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Monday, September 15th. Wall Street Zen upgraded Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 16th. Finally, BTIG Research increased their target price on shares of Theravance Biopharma from $24.00 to $25.00 and gave the stock a “buy” rating in a report on Friday, June 27th. Two analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $23.00.

Theravance Biopharma Stock Up 1.0%

NASDAQ TBPH opened at $14.28 on Friday. The company has a market cap of $719.14 million, a price-to-earnings ratio of 59.50 and a beta of -0.03. Theravance Biopharma has a twelve month low of $7.90 and a twelve month high of $15.15. The business’s fifty day moving average is $14.03 and its 200 day moving average is $11.67.

Institutional Trading of Theravance Biopharma

A number of institutional investors and hedge funds have recently modified their holdings of TBPH. Tower Research Capital LLC TRC grew its holdings in shares of Theravance Biopharma by 18.5% in the second quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock worth $55,000 after acquiring an additional 781 shares during the period. SG Americas Securities LLC bought a new stake in shares of Theravance Biopharma during the 3rd quarter worth approximately $101,000. AQR Capital Management LLC bought a new stake in Theravance Biopharma during the 1st quarter valued at about $101,000. R Squared Ltd raised its position in Theravance Biopharma by 636.6% during the 1st quarter. R Squared Ltd now owns 12,522 shares of the biopharmaceutical company’s stock valued at $112,000 after purchasing an additional 10,822 shares in the last quarter. Finally, Tabor Asset Management LP bought a new stake in shares of Theravance Biopharma in the 1st quarter valued at about $135,000. Institutional investors own 99.10% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.